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Summary 
Sera from chagasic patients possess antibodies recognizing the carboxy-terminal  part of the ribosomal 
P0 protein of Trypanosoma cruzi and the second extracellular loop of the human fll-adrenergic 
receptor. Comparison of both peptides showed that they contain a pentapeptide with very high 
homology (AESEE in P0 and AESDE in the human fll-adrenergic receptor). Using a competi- 
tive immunoenzyme assay, recognition of the peptide corresponding to the second extracellular 
loop (H26R) was inhibited by both P0-14i (AAAESEEEDDDDDF) and P0-fl (AESEE). Con- 
comitantly, recognition of P0-fl was inhibited  with the H26R peptide.  Recognition of P0 in 
Western blots was inhibited by P0-14i, P0-fl,  and H26R, but not by a peptide corresponding 
to the second extracellular loop of the human fl2-adrenergic receptor or by an unrelated pep- 
tide. Autoantibodies  affinity purified with the immobilized H26R peptide were shown to exert 
a positive chronotropic effect in vitro on cardiomyocytes  from neonatal rats. This effect  was blocked 
by both the specific fll blocker bisoprolol  and the peptide P0-fl. These results unambiguously 
prove that T. cruzi is able to induce a functional autoimmune response against the cardiovascular 
human fll-adrenergic  receptor through a molecular mimicry mechanism. 
C 
hronic Chagas' heart disease, resulting from infection 
with the protozoan Trypanosoma cruzi, is a slowly evolv- 
ing inflammatory cardiomyopathy that may lead to severe 
cardiac dilatation, congestive heart failure, and death (1). The 
histological picture includes degeneration of cardiomyocytes, 
coexisting with fibrosis and mononuclear cell infiltration, ap- 
parently occurring in the absence of parasites. These features 
suggest that an autoimmune component could be involved 
in the pathogenesis  of the disease (2). 
The occurrence of an autoimmune process leading to chronic 
myocardial injury may result from a parasite-induced deregu- 
lation of the immune system, leading to loss of tolerance for 
self-antigens or to a T. cruzi-induced  cross-reactive immune 
response to self-antigens (molecular  mimicry). 
Although there is increasing evidence of antibodies  and 
T cells cross-reactive for T. cruzi and mammalian antigens, 
only a few of the latter have been identified (3-7). To our 
knowledge, only two cross-reactive B cell epitopes have been 
identified and mapped: a dodecapeptide derived from the se- 
quence of a  T.  cruzi  flagellum-associated  surface protein 
generate antibodies  that cross-react with a 48-kD  nervous 
tissue antigen (8), and the 13 carboxy-terminal amino acids 
of the low molecular weight T. cruzi ribosomal P proteins 
generate antibodies that cross-react with their human coun- 
terparts  (9-11). 
Another ribosomal  P protein of the parasite, named P0 
with a molecular mass of 38 kD, is also antigenic in human 
T. cruzi infection (12, 13). This protein contains long, nega- 
tively charged stretches, which have been shown to be as- 
sociated with autoantigens  in SLE (14) and to give rise to 
polyreactive autoantibodies after experimental T. cruzi infec- 
tion (15). It was recently proposed that the autoantibodies 
against the/31-adrenergic  receptor (16) and the M2 acetyl- 
choline receptor (17), detected in patients with idiopathic di- 
lated cardiomyopathy, could be directed against a negatively 
charged sequence present on the putative second extracellular 
loop of these receptors (18). On the other hand, since func- 
tionally active autoantibodies against/3-adrenergic receptors 
(19, 20) and M2 muscarinic acetylcholine receptors of the 
heart (21) have been observed in patients with Chagas' dis- 
59  J. Exp. Med. ￿9  The Rockefeller  University  Press ￿9 0022-1007/95/07/0059/07  $2.00 
Volume 182  July  1995  59-65 ease, the epitopes recognized by these autoantibodies should 
be localized in the same receptor domain. Therefore, a pep- 
tide corresponding to the second extracellular loop of the 
human  Bl-adrenergic  receptor was  used  to  screen for the 
presence of antireceptor autoantibodies and to affinity purify 
such antibodies from sera of patients  with Chagas'  disease 
for functional characterization. 
In view of the extremely high similarity between a pen- 
tapeptidic sequence in the P0 ribosomal protein from T. cruzi 
and  the human ~/1-adrenergic receptor (Fig.  1),  using  im- 
munochemical and cell physiological techniques, the hypothesis 
was tested for possible cross-reactivity between the anti-P0 
antibodies  and  the  functionally  active  anti-B1  adrenergic 
receptor autoantibodies. 
Materials  and Methods 
Sera of Patients.  Sera were obtained from chronically infected 
chagasic individuals (n  =  36) from the same endemic region, lo- 
cated in northwest Argentina. These individuals  were evaluated 
at the Servido de Cardiologia, Ramos Mejia Hospital (Buenos Aires, 
Argentina) by clinical examination, resting electrocardiography,  aj- 
maline tests,  and M  and B node echocardiography. The T. cruzi 
infection was assessed by complement fixation, passive hemagglu- 
tination, and immunofluorescence. Sera of a group of healthy blood 
donors (n  =  8) were included as controls. The sera sampled from 
15 individuals  infected with Leishmania species included 6 samples 
from patients with kala-azar and 9 samples from patients with syl- 
vatic leishmaniasis.  These sera reacted in an immunofluorescence 
test with Leishmania donovani promastigotes. They were provided 
by Dr. M. E. Camargo (Laboratory Fleury, Sao Paulo, Brazil) and 
by A. Luquetti (Laboratorio Pesquisa de Chagas,  Goiania, Brazil). 
The IgG fractions of two patients with idiopathic dilated cardio- 
myopathy, which induced a positive chronotropic effect in neonatal 
rat cardiomyocytes,  were used. 
Peptides.  Peptides were synthesized by the solid-phase method 
developed by Merrifield (22) using a 430A automated peptide syn- 
thesizer (Applied Biosystems, Inc., Foster City, CA). The peptides 
were purified by HPLC and verified by amino-terminal sequencing. 
The sequences  of the peptides used are summarized in Fig.  1. 
PEPTIDES 
PEPTIDES DERIVED FROM T  CRUZI 
PO-14I  AAAESEEEDDDDDF 
po-/9  AESEE 
Peptides derived from the human ~-adrenoceptors 
H26R (B1)  HWWRAESDEARRCYNDPKCCDFVTNR 
H26Q (B2)  HWYRATHQEAI NCYANETCCDFFTNQ 
Unrelated peptide derived from tobacco mosaic virus coat protein 
TMVP  RNR I I EVENQ 
Figure 1.  Sequence  of the peptides  used. P0-14i  corresponds  to sequence 
56-68 of C-P0 (12). H26R corresponds  to sequence  197-222 of the human 
31-adrenergic receptor (38), and H26Q corresponds to sequence 172-197 
of the human Bz-adrenergic  receptor (39). TMVP corresponds to sequence 
90-99 of the coat protein of tobacco mosaic virus. 
Enzyme Immunoassay.  50 #1 of peptide (10 #g/ml) in 100 mM 
Na2CO3,  pH 11, was coated for 1 h on microtiter plates  (Nunc, 
Kastrup, Denmark).  The wells  were then saturated with PMT, 
which is PBS (10 mM phosphate,  140 mM NaC1,  pH 7.4)  sup- 
plemented with 3% (wt/vol) skim milk and 0.1% Tween 20 (Merck, 
Darmstadt, Germany). 50/~1 of sera or IgG fractions, diluted from 
1:50 to 1:200, was added to the saturated microtiter plates at 4~ 
overnight. After washing the wells three times with PBS plus 1% 
Tween 20, an affinity-purified biotinylated rabbit anti-human IgG 
(H+L) was allowed to react for 1 h. After three more washings, 
the bound biotinylated antibody was detected by incubating the 
plates for 1 h with streptavidin-peroxidase (1 #g/ml) solution in 
PMT. This was foUowed by three washings in PBS and the addi- 
tion of substrate 2.5 mM H202, 2 mM 2,2'-azino-di(ethyl-benz- 
thiazoline) sulfonic acid (Sigma  Chemical Co., St. Louis,  MO). 
Optical densities were read after 30 min at 405 nm in a microplate 
reader. 
Competitive Immunoassay.  Before using the sera in the enzyme 
immunoassay as previously described, serum samples diluted at 1:200 
were incubated with increasing concentrations of peptides for I h 
at room temperature. 
Purification of Recombinant jS-Galactosidase Fusion Protein C-PO. 
Escherichia coli RY-1089 lysogenic for the Xgt11 wild-type and Xgt11 
recombinant C-P0 phage were cultured from single colonies at 32~ 
shifted to 42~  for 25 min, and induced with 10 mM isopropyl 
3-D-thiogalactopyranoside for 2 h (23). The bacteria were pelleted 
and lysed,  and 3-galactosidase  wild-type or fusion protein was 
purified as described previously (12, 24). Briefly, the fusion protein 
was  purified  with  a  ProtoSorb  lacz  column  (Promega  Corp., 
Madison, WI) following the instructions of the manufacturer. The 
purity was  assessed by SDS-PAGE and Western blot analysis. 
Western Blots.  Purified proteins were analyzed by denaturing 
SDS-PAGE,  using  5%  stacking  and  7.5%  running  gels  (25). 
Western blot analysis was performed according to a standard method 
(26). The nitrocellulose transfers were blocked with 5% dried skim 
milk powder in Tris-buffered  saline, pH 7.4, supplemented with 
0.1% Tween 20, probed with sera (dilution 1:200), and adsorbed 
with 20% E. coli lysate. For peptide inhibition experiments, pep- 
tides were added at 30/~M.  Antibody detection was performed 
with the Vectastain ABC kit (Vector Labs, Inc., Burlingame, CA). 
Antibody  Purification.  The IgG fraction of the sera was  pre- 
pared by dilution of the sera 1:5 in PBS and precipitation at 40% 
(NH4)2SO4 saturation. The precipitate was redissolved in PBS at 
a 1:1 dilution. 
The H26R peptide was coupled to activated CNBr-Sepharose 
(Pharmacia  Diagnostics AB, Uppsala,  Sweden) according to the 
standard  procedure. 
The IgG fraction was incubated overnight at 4~  with 300 mg 
of H26R-Sepharose. The gel was washed seven times by centrifu- 
gation for 5 rain at 200 g before elution with 0.2 M glycine buffer, 
pH 2.8. The elution volume was directly neutralized with 400 #1 
of 1 M Tris buffer, pH 8.0. The purified antibodies  were then dia- 
lyzed against PBS before use. 
Functional Activity of  the Affinity-purified Antibodies.  Cultured neo- 
natal rat heart myocytes were used as a functional test system (27). 
Single cells were dissociated  from the minced heart ventricle of 
1-3-d-old Wistar rats with a 0.25% solution of trypsin. The myo- 
cytes were cultured as monolayers on the bottom of 45-ml Mtiller 
bottles (1.2  x  106 seeded cells in 3 ml of medium) in SM20-I 
medium (Max Delbrfik Center, Berlin, Germany) containing 10% 
heat-inactivated calf serum and 2/~M fluorodeoxyuridine (the latter 
prevented proliferation of nonmuscle cells). They were cultured for 
4 d at 37~  in air. 
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at 37~  on a heated stage of an inverted microscope. The changes 
in beating frequency were measured 1 h after the addition of the 
antibodies. The basal beating rate was 160  _+  20 beats/min. 
Statistical Analysis.  Means  and standard deviations of the OD 
values obtained in the enzyme immunoassays were calculated by 
the STATVIEW program on a Macintosh computer. Positivity was 
defined as mean _+  2 SD of the OD at 405 nm of the sera from 
healthy donors (n = 8). Significance  between the different groups 
was assessed  by the ANOVA module of the STATVIEW program. 
Correlations between the responses against the different peptides 
were calculated by the correlation module of the same program. 
Results 
Enzyme Immunoassays.  Since the second extracellular loop 
of the human ~l-adrenergic receptor has been.shown to con- 
tain a functionally autoimmune B cell epitope (16), H26R 
recognition by sera of chagasic patients was assayed. Table 
I summarizes the results.  13 of 36 sera from chagasic patients 
were found to be positive compared with 0 of 8 control sera 
(P <  0.05). This response was compared against that of the 
immunodominant ribosomal P0 protein from T. cruzi (C- 
P0) and the peptide derived from it and thought to cross- 
react with the receptor (P0-B). As already shown elsewhere 
(12), >80% of the chagasic sera reacted with C-P0, whereas 
only 47% reacted with P0-/3. Although there was no corre- 
lation between the responses to H26R and C-P0 (P =  0.282), 
a significant correlation was found between the responses to 
H26R and P0-~ (P =  0.0147). The intensity of the response, 
as shown in Fig. 2,  increased  from H26R to C-P0. 
The specificity  of the response  against H26R and C-P0 
was assessed by assaying sera from 15 patients with leishman- 
iasis. None of them yielded a positive response. 
To study cross-reactivity  between the parasitic antigen and 
the human ~l-adrenergic receptor,  competitive immunoen- 
zyme assays were set up using H26R and P0-/8. As shown 
in Fig.  3, recognition of H26R was inhibited with H26R 
as a control inhibitor and P0-/3 or P0-14i, peptides derived 
from P0 of T. cruzi. Alternatively, recognition of P0-/3 was 
inhibited with P0-/3 as the control inhibitor and also with 
H26R.  An unrelated peptide derived from tobacco mosaic 
virus  coat  protein  (TMVP) 1 developed  no  inhibitory ca- 
Table  1.  Number of Patients with Sera Positive for the  Three 
Antigens 
Patients  H26R  C-P0  P0-/3 
Healthy controls 
(n  =  8)  0  0  0 
Chagasic patients 
(n  =  36)  13  30  17 
Leishmaniasis patients 
(n  =  15)  0  0  ND 
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Figure 2.  Enzyme  immunoassays  of the sera against  the different  pep- 
tides. Sera from healthy  blood donors (white bars) and sera from positive 
chagasic patients (black bars) were tested against the three peptides indi- 
cated on the abscissa. Numbers correspond to the serum dilutions  used. 
pacity. These results show the mean and standard deviation 
of competition experiments with four different sera. The broad 
standard deviation reflects the different sensitivities of the in- 
dividual sera toward the competitive peptides. 
Western Blots.  To ascertain  whether the results obtained 
with the peptides were also valid for the antigenic proteins, 
the  inhibitory effects  of the  peptides  on  recognition  of 
ribosomal protein P0 (C-P0) of T. cruzi expressed in E.  coli 
were investigated. 
Two sera, used for the competitive enzyme immunoassays, 
were tested (Fig. 4). Preincubation of the antisera with the 
antigen (C-P0) completely abolished recognition of the elec- 
trotransferred protein, showing that the competition condi- 
tions were adequate. The peptides P0-14i, P0-B,  and H26R 
completely inhibited the recognition of the C-P0 protein by 
serum 15 (Fig.  4 A), and recognition by serum 112 (Fig. 4 
B) was highly decreased  in the presence  of these peptides. 
Two peptides, one corresponding to a sequence of TMVP and 
the other to the second extracellular loop of the B2-adrenergic 
receptor,  were used as negative controls. The first peptide 
did not show any effect, whereas the second peptide had only 
a small effect on recognition of P0 by serum  15. 
Functional Activity  of the Anti-H26R  Antibodies.  Specific 
anti-H26R antibodies were affinity  purified to assay for func- 
tional recognition of the ~/1-adrenergic using spontaneously 
beating neonatal rat heart myocytes. Since this system has 
already been used for the study of anti-receptor  autoantibodies 
in idiopathic dilated cardiomyopathy (27) and the sequences 
of the second extracellular loop of rat and human/31-adren- 
ergic receptors are totally similar (28), it is suitable for cross- 
reactive studies.  To increase the specificity of the functional 
response, assays were performed in the presence of 1 ~M atro- 
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Figure 3.  Competition enzyme immunoassay with the cross-reacting 
peptides. Results  show the mean  -+  SD of the percent inhibition with 
increasing  amounts for four sera. (.4) Inhibition  of  recognition of the H26R 
peptide  with H26R (--O-), P0-3  (--t~),  P0-14I (--Z~), and TMVP 
(-2k-). (B) Inhibition of recognition of the P0-3 peptide with H26K, 
P0-B, and TMVP.  Symbols are the same as in A. 
Figure 4.  Immunoblots  of recombinant C-P0 and inhibition  with pep- 
tides. Immunoblots  and inhibitions  are shown for two different sera. The 
inhibitory proteins and peptides defined  under the different  lanes correspond 
to the structures  shown in Fig.  1. The amount of protein blotted was 
,ol/~g. The inhibitory concentrations  of peptides was 30/~M, 
body-peptide complex had no toxic effects on the cells, the 
cardiomyocytes  were treated with  10/zM isoproterenol, a 
3-adrenergic agonist. The cardiomyocytes reacted in a normal 
way to this stimulant. 
In contrast, 20 #g/ml peptide did not inhibit the positive 
chronotropic effect of IgG fractions from patients with idio- 
pathic dilated cardiomyopathy. (Fig.  5). 
pine to avoid any interference with autoantibodies directed 
against the muscarinic acetylcholine receptor, which are present 
in sera of chagasic  patients (21). 
The purified antibodies showed the same positive chrono- 
tropic response as those purified from patients with idiopathic 
dilated cardiomyopathy (29). After a 60-min preincubation 
with the antibodies, a significant increase in beating frequency 
of the heart  myocytes was  observed;  this was completely 
blocked by the addition of the Bl-specific blocker bisoprolol. 
When the antibodies were preincubated with  14/xg/ml 
PO-B before  addition to  the  cardiomyocytes,  the positive 
chronotropic effect of the purified antibodies was inhibited 
completely for the antibodies purified from patient 99 and 
partially for those from patient 32.  Peptides  alone did not 
have any effect on the cardiomyocytes. To ensure that the anti- 
Discussion 
Molecular mimicry by T. cruzi is evidenced by the exis- 
tence of cross-reactive antibodies to T. cruzi and mammalian 
cells. These autoantibodies were characterized  by immuno- 
blots on target tissues and/or immunocytochemical  localiza- 
tion of immunologically cross-reactive material on the same 
tissues. The existence of autoantibodies that could interfere 
with the functional properties of the target cells was inferred 
from the physiological activity of IgG fractions isolated from 
patients with Chagas' disease (19, 21). The structural deter- 
mination of the second extracellular loop as the antigenic re- 
gion recognized by functionally active autoantibodies against 
the 3l-adrenergic receptor in idiopathic dilated cardiomyop- 
athy (16) prompted us to look for a possible sequence similarity 
between this domain and major antigenic proteins of T. cruzi. 
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Figure  5.  Agonist-like  effect  of affinity-purified  anti-H26R autoanti- 
bodies. Autoantibodies  affinity  purified  from  two different  sera  were added 
at a 1:100 dilution  to neonatal  rat cardiomyocytes  in culture, and the in- 
crease in beating  frequency  was determined.  Means _+ SEM of 10 different 
measurements are shown. The final antibody  concentration  for patient 
32 was 4 nM; that for patient 99 was 10 nM. 
The specificity  of the effect was studied by inhibition with the B1- 
specific antagonist  bisoprolol (1/~M) and the peptide P0-B (18 #M). IgG 
fractions  from  two patients  with idiopathic  dilated  cardiomyopathy  (IDCB 
and IDCR) were tested in the absence and presence of P0-~. No inhibi- 
tory effect  of the peptides  was observed. The cells studied  for peptide  inhi- 
bition with the antibodies of both patients were subsequently  stimulated 
with the B-adrenergic  agonist  isoproterenol  (10/.tM). The results obtained 
in the presence of antibody  from patient 99 and peptide P0-/3 are shown. 
A  pentapeptide derived from the P0 ribosomal protein of 
T. cruzi  showed high similarity with a pentapeptide in the 
receptor loop. The results presented here show not only that 
this peptide is a cross-reacting B cell epitope, but also that 
it is important for the functional activity of the autoanti- 
bodies on the receptor. 
The fact that the second extracellular loop of the human 
/3vadrenergic receptor  is  recognized by autoantibodies in 
two cardiomyopathies with different etiologies confirms our 
proposed hypothesis that this domain of G protein-coupled 
receptors  can be tagged as a main immunogenic region in 
the sense given to the region recognized by anti-nicotinic 
acetylcholine receptor autoantibodies in myasthenia gravis (30). 
The second extracellular loop, however, contains several epi- 
topes that have functional meaning. This may be concluded 
from the fact that the pentapeptide P0-/3 only partially in- 
hibited the functional effect in one of the patients and did 
not inhibit at all the functional autoantibodies found in idio- 
pathic dilated cardiomyopathy (Fig.  5). These results are in 
agreement with the observations that in idiopathic dilated 
cardiomyopathy, the peptide encompassing the cross-reactive 
epitope did not block the functional effect of the autoanti- 
bodies,  but a neighboring heptapeptide (ARRCYND) did 
(31). These results suggest that recognition by autoantibodies 
of different B cell epitopes, present on the second extracel- 
lular loop, could lead to the same stimulatory effect. They 
also confirm that, as may be expected from the molecular 
mimicry hypothesis, recognition of the cross-reactive epitope 
is limited to patients infected with the parasite. 
The fact that  autoantibodies against both B-adrenergic 
receptor subtypes (B1 and/32)  have been observed  in sera of 
patients with Chagas' disease (32) suggests that another func- 
tionally important B  cell  epitope may be localized at the 
carboxy-terminal end of the second extracellular loops, which 
show the highest similarity  between the two receptors (Fig. 1). 
The cross-reactivity between a ribosomal protein and a 
membrane receptor as described here may also be relevant 
to the existence  of cross-reactive  membrane-related targets 
on human cells for autoantibodies against ribosomal proteins 
in SLE (33). Indeed, it gives further support to the hypothesis 
that autoantibodies against intraceUular targets have pathogenic 
importance when they cross-react with membrane proteins. 
It is worthwhile to note that autoantibodies against the mito- 
chondrial ADP-ATP cartier, known to be present in idiopathic 
dilated cardiomyopathy (34),  similarly seem to functionally 
recognize Ca  2+ channels on cardiac  myocytes (35). 
Although idiopathic dilated cardiomyopathy  is considered 
an autoimmune disease (36), it does not answer to the Witeb- 
sky criteria  as  recently revised  (37).  In contrast,  Chagas' 
disease-both human and experimental-has been forwarded 
as a model for autoimmune disease (2). The common exis- 
tence of autoantibodies directed against the same receptors 
in both diseases could shed light on their pathogenic impor- 
tance. Since the specific anti-/3vadrenergic receptor response 
seems to be absent in leishmaniasis,  another parasitic disease 
with an autoimmune cellular component, molecular mim- 
icry is  probably more  important  than a  parasite-immune 
deregulation in the onset of the autoimmune disease. 
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